TrialThe New England journal of medicine2026
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D.
Tarik Asselah et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papercites it
TrialThe New England journal of medicine2026
Tarik Asselah et al.PubMed ↗Publisher ↗
No numbers read from the abstract.